• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A hypotriglyceridemically active polysaccharide having the following characteristics: (a) Specific rotatory power: (1.8 w/v% solution) (b) Molecular weight by gel filtration: (c) Sugar composition (weight percent by gas chromatography) (d) Acid-base characteristic: neutral polysaccharides (e) Physiological characteristics: capable of reducing the blood triglyeride in mammals. This hypotriglyceridemically active polysaccharide can be prepared by cultivating a microorganism belonging to the genus Streptococcus in an adequate culture medium therefor; and collecting the hypotriglyceridemically active polysaccharide from the cultured cells of the microorganism and/or the supernatant of the culture broth. The present hypotriglyceridemically active polysaccharide can be used as an active ingredient of a hypotriglyceridemic or antithero- sclerotic pharmaceutical composition together with pharmaceutically acceptable carrier therefor to form a hypotriglyceridemic or antiatherosclerotic pharmaceutical composition, which is suitable for oral administration to mammals.
    公开号:SU1732815A3
    申请号:SU843770904
    申请日:1984-07-26
    公开日:1992-05-07
    发明作者:Каваи Ясуо；Язава Казунага
    申请人:Кабусики Кайся Эдванс Каихацу Кенкюдзе (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to methods for producing hypoglyceride-active polysaccharides, i.e. polysaccharides that reduce the content of triglyceride in the blood of mammals.
    Substances of this type of action can be used as therapeutic drugs against atherosclerosis or hyperlipidemia, which are the most. more typical diseases of middle and elderly people.
    A method of obtaining a physiologically active polysaccharide by cultivating producer strains from the genus Pseudomonas on an appropriate nutrient medium and isolating it from the fermentation broth by fractionating biopolymers 1.
    The disadvantage of the method is the insufficiently high physiological activity of the polysaccharide.
    The aim of the invention is to increase the activity of the target product.
    FIG. 1-4 shows the chromatogram. Explaining the proposed method.
    The inventive method for producing gipotrig- litseridalno-active polysaccharides consists in that in a nutrient medium - Rogoza broth - and aerobically grown-producing strains of Streptococcus faecium PERM BP-296 or Streptococcus faecalis PERM BP-297, or Streptococcus savlum BP-298, or Streptococcus salivalls
    Xi
    CJ GO 00
    d
    ate

    Oj
    PERM BP-299, or Streptococcus durans PERM BP-300, or Streptococcus mltls PERM BP-301, or Streptococcus equlnus PERM BP-302, to maximize the filling of the target product, separate the biomass from the culture fluid and release the target product from the culture fluid or from biomass after its deproteinization and disinfection.
    The most common examples of such microorganisms are deposited at the Fermentation Research Institute (IIF, i.e. International Storage Center in accordance with the Budapest Agreement) in Japan, and the storage ciphers are listed in Table 1.
    The microbiological characteristics of the microorganisms used in the proposed method are the same as the microbiological characteristics of known microorganisms belonging to the same class, i.e. general microbiological characteristics, cultivation methods and other properties correspond to the characteristics described in the Berg Manual on Specific Bacteriology, 8th ed.
    The most common microbiological properties of these strains are given in table 2 and 11.
    These microorganisms can be cultivated by a known method. For example, bacterial cells can be obtained by stationary cultivation in Rogus broth medium under aerobic conditions, then the bacterial cells are separated by centrifuging the culture.
    The composition of the medium of Rogoza broth is as follows: yeast extract 5; tryptosis 3; K2HP043; KH2P043; triammonium citrate 2; twin-80 1; glucose 20; cysteine hydrochloride 0.2, in addition, salt solution (1 MgS, 04 7H20 11.5; FeSCV7H20 0.68; MnS04 2H20 2.4; distilled water 100 ml) 1-5 ml and distilled water to 1 liter (pH 7, sterilized by heating to a temperature of 121 ° C, which is maintained for 15 minutes).
    Getting polysaccharide PSST.
    Growing microorganisms. Each of these microbial strains is seeded on Rogosa broth medium and incubated without stirring at 37 ° C for 5-10 hours under aerobic conditions, resulting in a culture broth with a certain concentration of live bacterial cells.
    The culture broth is continuously centrifuged at a speed of 12,000 rpm, and the collected bacterial cells are then washed in saline (0.85% NaCI) 2 or 3 times.
    The destruction of bacterial cells. The washed cells are suspended in physiological saline solution and thermally treated at 115 ° C for
    10 min for the purpose of their destruction.
    Bacterial cells, washed and suspended in physiological saline, are disrupted by French ultrasound (15 kHz, 60 min).
    5 press or other known methods.
    Remove fat from cells. The suspension of the destroyed cells is mixed with a mixture of chloroform-methanol (2: 1 v / v). The components extracted with an organic solvent are then completely removed by centrifuging at 300 rpm for 10 minutes, and the chloroform layer is drained.
    5 Processing by proteolytic enzymes. Fat-free samples are treated with proteolytic enzymes, such as pronase, trypsin, and pepsin, using known procedures. Of these proteolytic enzymes, pronaz is most preferred for this purpose. The conditions of treatment with this enzyme are known.
    Cleaning up Such precipitating agents, such as trichloroacetic acid or ammonium sulfate, are added to the upper layer after centrifuging the proteolytic reaction mixture so that the protein fraction precipitates and can be precipitated.
    0 delete. The upper layer fraction is then treated with an appropriate nuclease or proteolysis enzymes in order to remove nucleic acid components, such as DNA and RNA or proteins.
    5 fractions. After this enzyme treatment, dialysis is carried out several times.
    The partially purified fraction is then again subjected to other purification procedures, such as gel filtration and purification using a chromatographic column. A pure preparation of a polysaccharide, referred to as PSST polysaccharide, is obtained at the end of the last stage.
    In general, this PSST polysaccharide
    5 can be obtained in accordance with its physicochemical characteristics using numerous isolation and purification procedures that have been widely used in this technical field for a long time, such as precipitation-dissolution and extraction, solvent extraction, dialysis, chromatographic column, electrophoresis, gel filtration or any combination of these procedures. Thus, the invention is in no way limited to any of the specific procedures mentioned.
    Those. The preparation of the invention relates to methods for producing active products that lower triglycerides in the blood, which consist of a polysaccharide, and are obtained from microorganisms belonging to the Streptococcus family, since pharmacological activity was found in the polysaccharide fraction,
    Note that the activity for reducing the triglyceride content in the upper layer of the culture broth is about 1/5 of the activity in the bacterial cell.
    The physicochemical and physiological characteristics of the PSST polysaccharide are as follows.
    Chemical nature and properties of solubility. The finely ground sample obtained after desalting and freeze-drying is a non-hygroscopic white powder with high solubility (100 mg / ml) in water, but it only partially dissolves in ethanol, methanol and acetone and does not dissolve at all in ether and chloroform.
    Molecular Weight. The molecular weight of the PSST polysaccharide is estimated at about 14000 ± 3000 and is established by gel filtration using several programing materials of various molecular weights as indices, and Toyooparl HW / 55 columns (Toyosode Co., Ltd.), balanced by 25 mM Tris-HC buffer containing 0, ZM NaC (pH 7.5).
    Specific rotation rate. The specific rotation rate of the said PSST polysaccharide in a 1.8% solution, is + 190.1 (right rotation). This indicator is determined using a polarimeter (model DIP-4, Dzhapan Spectroscopic, Co., Ltd.).
    Sugar composition. 4 mg samples are treated with a 0.2 M solution of TFA (trifluoroacetic acid) at 100 ° C for 7 hours, and trimethylsilylation is carried out as follows: the sample is mixed with 0.2 ml of hexamethyldisilazane (20% in pyridine) and 0, 02 ml of trimethylchlorosilane, the mixture is stirred for 15 minutes and, after settling, for 5 minutes, subjected to gas chromatography q to determine the content of glucose, rhamnose, etc. The temperature of the separation column is 179 ° C. The content of uronic acid is determined using the carbazole-NACSM method (modified Bitter-Muir method).
    The composition of sugars polysaccharide PSST following,%: glucose 70,3; rhamnose 13.7; uronic acid 16.0.
    Acid-base characteristics. The pH of 0.1 and 0.5% aqueous solution of PSST polysaccharide was 6.71.
    Infrared Absorption Spectrum. The infrared absorption spectrum of the PSST polysaccharide obtained using an infrared spectrometer (module IASLO A 302, Japan Spectroscopic Co., Ltd.) is shown in FIG. 1, where the wavelength and transmittance, respectively, are plotted along the abscissa and ordinate.
    Elementary analysis. Elemental analysis using an elementary analyzer (model 240 V, Perkin-Elmer) gave the following result: C 37.2%, H 6.4% and O 56%, for the PSST polysaccharide. The simplified formula has the following form.
    C31H64N35.
    Melting point. The melting point of the PSST polysaccharide was 235-241 ° C, and it was measured using a melting point temperature measuring device (Jaanako MP-3 model, Jaanagimoto Seisakusho, Japan).
    Physiological characteristics. The PSST polysaccharide is active when used to reduce the amount of triglyceride in the blood of a mammal in a dental application.
    This activity is stable in the temperature range from -80 ° C to 115 ° C and at a pH in the range from 4.1 to 11, even if the polysaccharide has been stored before use.
    Pharmacological action of PSST polysaccharide.
    Pharmacological effects. The proposed anti-atherosclerotic preparation containing the proposed PSST polysaccharide is extremely effective in reducing the amount of triglyceride in mammalian blood. Accordingly, the proposed preparation is used as a therapeutic or prophylactic preparation for diseases associated with atherosclerosis, hyperlipidemia, hyperlipoproteinomy, xanthomatosis, cholecystolysis, hypertension, diabetes and other diseases.
    The proposed composition can be applied to dental mammals, intraperitoneal intravenous or any other methods. amount
    a single dose should be from about 1 mg to 0.5 g / kg body weight. For oral administration, in a preferred embodiment, the amount per dose is from about 0.01 mg to 100 mg / kg body weight. For the use of a drug, any of its form can be chosen: it can be used as a solution in physiological saline or in other carriers, as injections, made by means of lyophilization, etc., as suppositories, tablets coated, granules, tablets, capsules, etc. with appropriate carriers and diluents.
    Acute toxicity. The indicated value for the proposed PSST polysaccharide is more than 1200 mg / kg body weight for intraperitoneal use in mice. The proposed material is substantially non-toxic in dental use.
    Example Preparation and purification of PSST polysaccharide. Streptococcus faectum FERM BP-296 are inoculated into 2 liters of Rogus broth medium with a final cell concentration of 1x106 bacteria / ml. The medium after vaccination is cultivated for 10 hours at 37 ° C without mixing under aerobic conditions, in order to obtain a culture broth with a cell concentration of 10 bacteria / ml. Bacterial cells were harvested by continuous centrifugation at 12,000 rpm, washed with physiological saline (0.85% NaCI) and suspended in this solution so as to obtain 100 ml of cell suspension with a concentration of 2x1010 bacteria / ml.
    The bacterial cell suspension was treated at 115 ° C for 10 minutes and treated 3 times with a mixture of chloroform-methanol (2: 1 V / V) in order to remove fat.
    The defatted bacterial suspension is centrifuged at 3000 rpm for 10 minutes, and the bottom layer, i.e. the chloroform layer is removed. The aqueous layer is used as a starting material in the following purification steps.
    The starting material is then treated with 20 mg of pronase (sigma protease type X1Y) in 100 ml of phosphate buffer (pH 7.8) containing 0.0015 mg of CaCl2 at 47 ° C for 24 hours, and then treated with 10 mg of pronase at the same conditions.
    The material treated with pronaza is divided into a precipitated fraction and a fraction of the upper layer after settling at
    centrifugation assistance — at 3,000 rpm for 10 minutes.
    1/9 volume of a 100% (w / v) solution of trichloroacetic acid (TCC) is added to the upper layer fraction, kept at 4 ° C for 3 hours with stirring, and then the resulting material is subjected to centrifugation at a speed of 3000 rpm for 10 min, resulting in
    0 get sediment and top layer. The same volume of 10% TCA solution is added to the precipitated fraction and the procedure described is repeated. The resulting upper layer is washed 3 times with ethyl simple
    5 With ether in order to remove TCC, dissolved in 50 ml of distilled water, neutralized with 1N. solution of NaOH, dialyzed to completely remove TCC and, finally, lyophilized so as to
    0 get 258 mg (dry weight) fraction of the upper layer.
    The resulting fraction of the upper layer is treated with pronase, dialyzed, and as a result I get 176 mg
    5 (dry weight) dialyzed fraction (MB 3500). Hereinafter, the dialyzed fraction will be referred to as the purified fraction I.
    The purified fraction I is subjected
    0 fractionation using a Sephadex T-100 chromatographic column (Pharmacia), balanced with 0.05 M Tris-HCl buffer. The resulting chromatogram of the purified fraction I at
    5, the elution rate is 1 ml / min, shown in FIG. 2, where the elution volume is deposited on the abscissa, and the concentration of the eluted material is plotted along the ordinate axis. The fraction after 124 ml is collected and later we will call it the purified fraction II (dry weight 93.6 mg).
    Fig. 3 shows the chromatogram of the purified fraction II, which was obtained using a Toioperal HW 5 55F column, equilibrated with 25 mM Tris-HCl buffer containing 0.3 M NaCI.
    The elution rate was 1 ml / min. In FIG. 3, curves 1–3 are the elution profiles of sugar, protein, and nucleic acid, respectively.
    Purified PSST polysaccharide (87.9 mg
    dry weight) is isolated by selection
    portions eluted in fractions
    80 100ml
    5 Figure 4 shows the chromatogram of the PSST polysaccharide under the same esperimental conditions that were used for FIG. 3.
    Table 3 shows the quantitative yield of the protein, which was determined by Lowry's year, the RNA, which was determined by the method of orsinol, the DNA, which was determined by the method of diphenylamine, and the sugar, which was determined by the method of phenol-NAZSM in each method of preparation.
    The specific activity shown in Table 3 indicates the relative activity in reducing the triglyceride levels of each fraction when tested in rats per unit weight, with the activity of heat-treated bacterial cells equal to 1. Methods of analysis for determining the activity of reducing the triglyceride in animals are described in example 2.
    It has been established that PSST polysaccharide can be isolated and purified from other bacterial strains listed in Table 1, by analogy with the present example, but with a lower yield.
    PRI mme R 2. Pharmacological effect of the PSST polysaccharide.
    Triglyceride reduction activity.
    1. Samples of saline, containing the equivalent of 16 mg / kg body weight of the lyophilized polysaccharide PSST, are obtained in a similar way. These samples are applied by the oral method in a daily dose of 1 ml in rats (age 18 weeks, males, average weight 246 g, 10 rats per group) and sterile mice (age 18 weeks, males, average body weight 30 g, 10 mice per group ). Rats and mice are fed for 8-12 weeks. Arterial blood is then collected from the abdominal aorta of these animals, and serum samples are separated by centrifuging the whole blood. The content of TG WACO triglyceride (Waco Yuniake Co., Ltd., Acetyl-acetone method) is determined.
    The results obtained are summarized in Table 4 (the degree of reduction of -no compared with the values in the control groups to which the described treatment was not applied)
    The composition of the diet used during the feeding period is shown in Table 5.
    2. Carboiled samples are applied orally by the oral method in a daily dose of 1 ml to normal rats (age 18 weeks, males, average animal weight 238 g, 15 rats in a group) and to ordinary sterilized mice (age 18 weeks, males, average weight animal 31 g, 10 mice per group) for 4 weeks. The blood triglyceride content is determined exactly as described. The results obtained are summarized in Table 6 (the degree of reduction compared with the values.
    obtained for the untreated control group).
    3. Physiological saline samples containing 4 mg / ml of PSST polysaccharide, 5 are applied orally in a daily dose of 1 ml per rat for 2 weeks to rats suffering from hyperlipidemia (18 weeks old, males, average animal weight 250 g , 5 rats per group) fed with cholesterol rich food. The content of triglyceride in the blood is determined in accordance with the above description. The results are summarized in table 7.
    5 Reactions to various doses. Physiological saline samples, containing from 0.1 to 20 mg / ml of PSST polysaccharide, are applied by oral method in a daily dose of 1 ml per ordinary rat (age 6 weeks, males, average animal weight 216 g, 5 rats per group) in for 4 weeks. The content of triglyceride in the blood is determined by the indicated methods (the group of unbroken rats was used as a control group). The results obtained are summarized in table 8.
    Acute toxicity. Physiological saline samples (0.5 ml / mouse) containing 1.10 and 100 mg of PSST polysaccharide are administered intraperitoneally in mice to 1C (6 weeks old, average weight 31.6 ± 0.6 g, 10 animals per group). Tanatobiological observations of mice were carried out for 14 days. The control material was physiological saline.
    The value of LDso, calculated in accordance with the method of Behrens-Kerber, was more than 1200 mg / kg of animal weight. With
    For dental use, the proposed material is essentially non-toxic.
    Pharmaceutical compositions.
    1.25 mg of purified polysaccharide 5 PSST thoroughly mixed with 275 mg
    powder of purified starch, and then tablets are made from the resulting mixture for dental use. Each tablet thus prepared corresponds to a dose of 101 heat-treated cells / kg body weight for an adult patient weighing 50 kg.
    2. The PSST polysaccharide is thoroughly mixed with diluents, such as
    5 calcium carbonate, lactose, etc., lubricants, such as stearic acid, talc, etc., and other additives, and then from the resulting mixture get tablets for dental use. Daily Polysaccharide Dose
    The PSST generally ranges from 01 to 100 mg / kg body weight.
    3. The PSST polysaccharide (900 mg) is suspended and dissolved in distilled water (30 ml), flavoring syrup is added, and then the composition is prepared as a syrup.
    Example Preparation and purification of TP5 polysaccharide.
    S.faecalis PERM BP-297, S avlum PERM BP-298, S. sallvarlus PERM BP-299, S.durans PERM BP-300, S.mltis PERM BP-301, S.equlnus PERM BP-302 are inoculated in a Rogosa bubble {2 L) at a final concentration of 1x10 bacteria / ml. The cultured medium was incubated for 10 hours at 37 ° C without stirring under aerobic conditions until 109 bacteria / ml culture were obtained. broth. Bacterial cells are then harvested by continuous centrifugation at 12,000 rpm, washed with saline (0.85% NaCl) and suspended in the same solution until 100 ml of cell suspension is obtained at a concentration of 2 x 1010 ml.
    The bacterial cell suspension was heat treated at 115 ° C for 10 minutes and treated three times with a mixture of chloroform and methanol (2: 1 v / v) in order to remove fats.
    The defatted bacterial suspension is centrifuged at 3000 rpm for 10 minutes and the lower layer, i.e. the chloroform layer is discarded. The aqueous layer is used as a starting material in the subsequent purification step. Then, the starting material is treated with 20 mg of pronase (sigma pronaza type XIV) in 100 ml of phosphate buffer (pH 7.8) containing 0.0015 mg of CaCl2 for 24 hours at 47 ° C, and then treated under the same conditions. mg pronase.
    The material treated with pronase is divided into precipitation and supernatant fractions by centrifuging at 3000 rpm for 10 minutes. 1/9 volume of 100 wt.% - trichloroacetic acid (TCA) is added to the supernatant fraction, left under stirring for 3 hours at 4 ° C, and then centrifuged at 300 rpm for 10 minutes to obtain a precipitation fraction and supernatant. The precipitation fraction is supplemented with the same volume of 10% TCA and the procedure is repeated. The resulting supernatant is washed 3 times with ethyl ether to remove
    The TCA is dissolved in 50 ml of distilled water, neutralized with 1N. NaOH is dialyzed to completely remove the TCA and finally lyophilized to obtain the supernatant fraction.
    The resulting supernatant fraction is treated with pronaz in the manner described and dialyzed to obtain a dialyzed fraction (MW 3500).
    This purified fraction is fractionated by chromatography on columns with Sephadex C-100, equilibrated with 0.05 M Tris-HCl buffer.
    The purified TPS polysaccharide is isolated
    by collecting the eluted portion in 80-100 ml fractions.
    The output of polysaccharides is given in table.9.
    The physicochemical properties of TPS polysaccharide are the same as those described.
    PRI me R 4. The pharmacological effect of TPS polysaccharide.
    These samples were administered by oral daily dosage of 10 mg / day / rat to standard rats (males at 18 weeks of age with an average weight of 238 g, each group contained 15 rats). The blood of the animals was analyzed for triglyceride levels.
    The degree of triglyceride reduction is shown in Table 10.
    权利要求:
    Claims (1)
    [1]
    The invention method for producing hypotriglyceride-active polysaccharides involves growing the producer strain on a nutrient medium containing sources of carbon, nitrogen, phosphorus, mineral salts, growth biostimulants and water under aerobic conditions up to maximum accumulation of the target product, separating the producer biomass with the formation of the flow of the culture fluid and the subsequent isolation and purification of the target product with its deproteinization, different
    in order to increase the activity of the target product, the strain S.faecium PERM BP-296 or S.faecails PERM BP-297 or S.savium PERM BP-298 or S.sallvalls is used as a producer strain.
    PERM BP-299, or S.durans PERM BP-300, or S.mltis PERM BP-301, or S.equinus PERM BP-302, Rhyoza broth is the nutrient medium, and the selection of the desired product is carried out from the culture fluid or from biomass after its deproteinization and disintegration.
    13
    1732815
    14 Table 1
    .T. and blitz 2
    Table 3
    Table 4
    Table 5
    15
    1732815
     A diet enriched with cholesterol (adding 1% cholesterol to the indicated diet)
     Diet, enriched with fructose (replacement by fructose of the total amount of wheat starch in the indicated diet)
    Table 7
    Table 6
    Table 8
    Table 9
    Table 10
    +
    +
    +
    2
    37
    +
    +
    +
    +
    +
    +
    +
    +
    Spheroid
    0.5-1.0 microns in diameter Pairs or chains in a liquid medium
    ± + 2
    37
    + 2
    37
    + +
    37
    +.
    1 +
    ±
     2,3,5-Triphenyltetra ash. was made.
    + 2
    37
    + +
    37
    3-7
    37
    +.
    1 +
    ±
    Concentration, ng / m -.
    %
    Transmission,% fe
    I
    N,
    0.4
    | 1 G
    s
    from th
    00
    ate
    one
    i
    AND
    200
    50100
    05yn elnshrovanz, ml (Рig.5
    ABOUT
    100- 0 & eroiou, ml
    4
    f5ff
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0101209B1|1989-01-11|Hypocholesterolemically and/or hypotriglyceridemically active products
    US4699787A|1987-10-13|Nitrogen-containing polysaccharide
    EP0455263A2|1991-11-06|Non-pyrogenic and non-irritating composition comprising sodium hyaluronate
    SU1732815A3|1992-05-07|Method for preparation of hypotriglyceridemic polysaccharides
    US4010258A|1977-03-01|Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
    US4812441A|1989-03-14|Hypocholesterolemically active protein derived from streptococcus
    IE47885B1|1984-07-11|Microbial fractions
    KR100197446B1|1999-06-15|Anti-cancer immunoactive polysaccharides separated from phellinus linteus and process for the preparation thereof
    US3875007A|1975-04-01|Lipid metabolism improving and anti-atheromatic agent
    EP0070656B1|1986-09-24|Immobilized superoxide dismutase, its production and pharmaceutical composition
    CA1276897C|1990-11-27|Hypocholesterolemically active rna fractions
    EP0196858A2|1986-10-08|Liver function-improving agent and blood pressure-lowering agent
    EP0207700B1|1992-09-02|Hypocholesterolemically and/or hypotriclyceridemically active rna fractions
    CA1122526A|1982-04-27|Biologically active substance, preparation processand drugs containing same
    WO1991018104A1|1991-11-28|Indh enzyme compositions and their methods of use
    SU1756349A1|1992-08-23|Strain bacteria corynebacterium sepedonicum - a producer of polysaccharide, inducing interferon production
    PL91664B1|1977-03-31|
    US3792160A|1974-02-12|Method of treating inflammation and composition therefor
    US3959467A|1976-05-25|Lipid metabolism improving and anti-atheromatic agent
    CA1211392A|1986-09-16|Preparation of an antibiotic selectively effectiveagainst staphylococcus infections
    RU2231364C2|2004-06-27|Method for preparing meliodosis pathogen capsule substance
    SU1750690A1|1992-07-30|Method for preparation of escherichia coli conjugated enterotoxin
    CA2123587A1|1993-05-27|Bactericide product; pharmaceutical composition and food additive containing the same
    KR100307460B1|2001-11-30|Food composition for inhibition of formation of aflatoxin using strain of rhizopus oligosporus
    JPH06219956A|1994-08-09|Immunostimulating agent
    同族专利:
    公开号 | 公开日
    EP0132981B1|1989-10-18|
    HUT34773A|1985-04-28|
    DD222895A5|1985-05-29|
    JPS6028401A|1985-02-13|
    EP0132981A2|1985-02-13|
    ES534629A0|1985-06-01|
    MX7693E|1990-08-24|
    PL248970A1|1985-04-09|
    AU3048884A|1985-01-31|
    PL147734B1|1989-07-31|
    ES8505722A1|1985-06-01|
    JPH0365362B2|1991-10-11|
    US4687764A|1987-08-18|
    CA1239364A|1988-07-19|
    HU191697B|1987-03-30|
    AU563995B2|1987-07-30|
    EP0132981A3|1986-01-29|
    DE3480217D1|1989-11-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5745558B2|1975-12-11|1982-09-28|
    US4251519A|1979-07-30|1981-02-17|Anheuser-Busch, Incorporated|Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels|
    JPS5943929B2|1979-08-13|1984-10-25|Satsuhoro Biiru Kk|
    JPS601877B2|1981-01-14|1985-01-17|Meiji Milk Prod Co Ltd|
    DE3305047A1|1982-02-19|1983-09-22|Terumo Kabushiki Kaisha trading as Terumo Corp., Tokyo|POLYSACCHARIDES, THEIR PRODUCTION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM|
    JPH0526768B2|1982-08-06|1993-04-19|Advance Kk|JPH0526768B2|1982-08-06|1993-04-19|Advance Kk|
    JPH0142280B2|1982-12-28|1989-09-11|Advance Kk|
    JPH0566370B2|1984-12-24|1993-09-21|Advance Kk|
    JPS625991A|1985-07-03|1987-01-12|Advance Res & Dev Co Ltd|Rna fraction having cholesterol or triglyceride lowering activity|
    US4851521A|1985-07-08|1989-07-25|Fidia, S.P.A.|Esters of hyaluronic acid|
    US5202431A|1985-07-08|1993-04-13|Fidia, S.P.A.|Partial esters of hyaluronic acid|
    US6756361B1|1997-10-14|2004-06-29|Nabi|Enterococcus antigens and vaccines|
    JP2009149523A|2006-03-01|2009-07-09|Ucc Ueshima Coffee Co Ltd|Immunostimulator and method for producing the same|
    CN103012615B|2013-01-08|2015-02-25|广东海洋大学|Method for efficiently extracting sepia acidic polysaccharose|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP58135982A|JPH0365362B2|1983-07-27|1983-07-27|
    [返回顶部]